LGND - LIGAND PHARMACEUTICALS INC

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 70.57

Open

$ 71.33

Bid

$ 70.56 x 100

Ask

$ 70.68 x 200

Day's Range

$ 70.53 - $ 72.04

52 Week Range

$ 49.24 - $ 94.57

Volume

88,152

Average Volume

Market Cap

1.25B

Beta (5Y Monthly)

$ 1.16

PE Ratio (TTM)

$ 24.03

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-29-2024	12-31-2023	10-K
2	11-09-2023	09-30-2023	10-Q
3	08-09-2023	06-30-2023	10-Q
4	05-08-2023	03-31-2023	10-Q
5	02-28-2023	12-31-2022	10-K
6	11-08-2022	09-30-2022	10-Q
7	08-09-2022	06-30-2022	10-Q
8	05-09-2022	03-31-2022	10-Q
9	02-28-2022	12-31-2021	10-K
10	11-09-2021	09-30-2021	10-Q
11	08-03-2021	06-30-2021	10-Q
12	05-06-2021	03-31-2021	10-Q
13	02-24-2021	12-31-2020	10-K
14	11-06-2020	09-30-2020	10-Q
15	08-07-2020	06-30-2020	10-Q
16	05-08-2020	03-31-2020	10-Q
17	02-27-2020	12-31-2019	10-K
18	11-08-2019	09-30-2019	10-Q
19	08-08-2019	06-30-2019	10-Q
20	05-09-2019	03-31-2019	10-Q
21	02-28-2019	12-31-2018	10-K
22	11-08-2018	09-30-2018	10-Q
23	08-08-2018	06-30-2018	10-Q
24	05-09-2018	03-31-2018	10-Q
25	03-01-2018	12-31-2017	10-K
26	11-09-2017	09-30-2017	10-Q
27	08-09-2017	06-30-2017	10-Q
28	05-09-2017	03-31-2017	10-Q
29	02-28-2017	12-31-2016	10-K
30	11-15-2016	09-30-2016	10-Q
31	08-04-2016	06-30-2016	10-Q
32	05-09-2016	03-31-2016	10-Q
33	02-26-2016	12-31-2015	10-K
34	11-09-2015	09-30-2015	10-Q
35	08-05-2015	06-30-2015	10-Q
36	05-11-2015	03-31-2015	10-Q
37	02-23-2015	12-31-2014	10-K
38	10-31-2014	09-30-2014	10-Q
39	08-05-2014	06-30-2014	10-Q
40	05-07-2014	03-31-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Benchmark Reiterates Buy on Ligand Pharmac...
04/12/2024 13:14:09

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $95 price target.

Ligand Pharmaceuticals Announces Topiramat...
04/08/2024 12:27:45

Captisol-enabled™ Topiramate Injection shown to be a substitute for an oral dose on a one-to-one basis

Ligand Pharmaceuticals Announces Launch Of...
04/03/2024 13:05:29

Pharmaceutical executive Scott Plesha named CEOLead product ZELSUVMI expected to be commercially available in late 2024Ligand P...

HC Wainwright & Co. Reiterates Buy on Liga...
02/29/2024 20:40:23

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...

Why Is Ligand Pharmaceuticals Stock Tradin...
02/27/2024 19:08:27

Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd ...

why-helix-energy-solutions-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Helix Energy Solutions Shares Are Trad...
02/27/2024 18:18:56

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

norwegian-cruise-line-posts-strong-sales-joins-hims--hers-health-sterling-infrastructure-and-other-big-stocks-moving-higher-on-tuesday

Norwegian Cruise Line Posts Strong Sales, ...
02/27/2024 15:27:54

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
02/27/2024 13:06:18

Ligand Reaffirms FY24 EPS Guidance Of $4.2...
02/27/2024 12:12:33

2024 Financial GuidanceLigand is reaffirming 2024 financial guidance introduced at its Investor and Analyst Day held on Decembe...

Ligand Pharmaceuticals Q4 EPS $1.38 Beats ...
02/27/2024 12:06:25

Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate o...

Earnings Scheduled For February 27, 2024
02/27/2024 10:01:31

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

Ligand Pharmaceuticals's Earnings: A Preview
02/26/2024 18:01:15

Ligand Partner Eisai Receives Approval In ...
02/22/2024 21:29:34

Fycompa® is the 16th Captisol-enabled™ product approved worldwideLigand Pharmaceuticals Incorporated (NASDAQ:LGND) today announ...

Henlius, Sermonix Enters Strategic Collabo...
01/11/2024 06:44:47

Ligand Pharmaceuticals Announced That The...
01/05/2024 21:32:28

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that the U.S.

Benchmark Reiterates Buy on Ligand Pharmac...
12/13/2023 15:47:42

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $95 price target.

Ligand Provides A 5-Year Outlook; Adjusted...
12/12/2023 17:07:49

The company provided an illustrative 5-year outlook, as follows:

Ligand Holds Investor And Analyst Day; Pro...
12/12/2023 17:06:37

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) hosted anInvestor and Analyst Day in New York City earlier today. CEO Todd Da...

Palvella Therapeutics And Ligand Pharmaceu...
12/01/2023 13:23:22

Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of C...

merck-highlights-data-on-new-vaccine-compares-tolerability-and-safety-to-pfizers

Merck Highlights Data On New Vaccine, Comp...
11/28/2023 17:03:10

Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigatio...